Classical Hodgkin Lymphoma
A RANDOMISED PHASE III TRIAL TO
ASSESS RESPONSE ADAPTED
THERAPY USING FDG-PET IMAGING
IN PATIENTS WITH NEWLY
DIAGNOSED, ADVANCED HODGKIN
LYMPHOMA
A randomised phase III trial to determine the role of FDG-P imaging in clinical stages IA/IIA Hodgkins disease.
A randomized, doubleblind, placebo controlled Phase 3 study of SGN35 (brentuximab vedotin) and best supportive care versus placebo and best supportive care in the treatment of patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant.
An open-label, multicenter, phase 2/3 clinical trial designed to provide the option of treatment with brentuximab vedotin (SGN-35) for patients who were allocated to the placebo treatment arm in the Phase 3 study SGN35-005 and experienced progression of HL during the study.